首页> 外文期刊>Cytopathology >Thyroid FNA diagnostics in a real‐life setting: Experiences of the implementation of the Bethesda system in Finland
【24h】

Thyroid FNA diagnostics in a real‐life setting: Experiences of the implementation of the Bethesda system in Finland

机译:现实生活中的甲状腺FNA诊断:芬兰贝塞斯达系统实施的经验

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction The Bethesda system is widely accepted for thyroid FNA diagnostics, but has scarcely been analysed in relation to clinical background data. Our aim was to analyse the thyroid FNA diagnostic process in view of clinical data, and to assess the validity of the Bethesda system during the first year of implementation. Methods There were 415 thyroid FNA s taken from 363 patients during October 2011‐September 2012 in the Pirkanmaa Hospital District, Finland. The median age of the patients was 59 years, and the female‐to‐male ratio 4:1. Clinical data were collected from patient registries, and thyroid FNA and histopathological data from the pathology registry. Results The Bethesda categories were represented as follows: 94 non‐diagnostic cases (26%); 177 benign (49%); 32 atypia of undetermined significance/follicular lesion of undetermined significance (9%); 31 follicular neoplasm (9%); 20 suspicious for malignancy (5%); and nine malignant cases (2%). Only 23 (24%) of the non‐diagnostic samples and 18 (56%) of the atypia of undetermined significance/follicular lesion of undetermined significance led to repeat FNA . Thyroid cancer was histopathologically diagnosed in 28 cases (8%). When the categories requiring surgical treatment were considered true positive findings, the sensitivity of the Bethesda system was 90%, and specificity was 70%. Interobserver accuracy was 86%. Conclusions Already during the first year of implementation, the Bethesda system proved reliable in evaluating the risk of thyroid malignancy. Nevertheless, the clinical judgement of the indication of ultrasound/ FNA and management according to the FNA findings need improvement. The relatively high proportion of non‐diagnostic FNA s could be diminished by obtaining the samples by radiologists experienced in ultrasound‐guided FNA techniques.
机译:简介贝塞斯达系统被广泛接受甲状腺FNA诊断,但几乎没有分析与临床背景数据有关。我们的目的是鉴于临床数据,分析甲状腺FNA诊断过程,并在执行第一年期间评估Bethesda系统的有效性。方法在2011年10月 - 2012年9月在芬兰皮克玛莎医院区患有415名甲状腺FNA S.患有363名患者。患者的中位年龄为59岁,女性对男性比例4:1。从病理登记处从患者注册表和甲状腺FNA和组织病理学数据收集临床数据。结果Bethesda类别表示如下:94例非诊断病例(26%); 177良性(49%); 32非典型明显显着性/卵泡病变的显着意义(9%); 31个卵泡肿瘤(9%); 20对恶性肿瘤可疑(5%);和九个恶性病例(2%)。仅23(24%)的非诊断样品和18(56%)的非典型缺陷的无明显显着性的显着意义导致了重复FNA。甲状腺癌组织病理学诊断为28例(8%)。当需要外科治疗的类别被认为是真正的阳性发现时,贝塞斯达系统的敏感性为90%,特异性为70%。 Interobserver精度为86%。结论已经在实施的第一年,贝塞斯达系统证明是评估甲状腺恶性肿瘤风险的可靠性。然而,根据FNA表现的超声/ FNA和管理指示的临床判断需要改进。通过以超声引导的FNA技术中经历的放射液学家获得样品,可以减少相对高的非诊断性FNA S.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号